Lettre aux partenaires d'AB Science concernant l’impact de la pandémie COVID-19 sur les études cliniques d’AB Science
07 avr. 2020 12h33 HE
|
AB Science
Paris, 7 avril 2020, 18h15 Lettre à nos partenaires concernant l’impact de la pandémie COVID-19 sur lesétudes cliniques d’AB Science Chers partenaires, À l'heure actuelle, nous prévoyons que...
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
26 mars 2020 16h07 HE
|
Equillium
EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., March ...
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
13 févr. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
AB Science fournit le résumé de la conférence web avec les principaux leaders d’opinion autour des résultats de la phase 3 du masitinib dans l’asthme sévère
02 déc. 2019 16h31 HE
|
AB Science
Paris, 2 décembre 2019, 22h15 Résumé de la conférence web avec les principaux leaders d’opinion autourdes résultats de la phase 3 du masitinib dans l’asthme sévère non contrôlé par les...
AB Science provides the summary of webcast with Key Opinion Leaders on masitinib Phase 3 results in severe asthma uncontrolled by oral corticosteroids
02 déc. 2019 16h31 HE
|
AB Science
Paris, 02 December 2019, 10.15pm Summary of webcast with Key Opinion Leaders on masitinibPhase 3 results in severe asthma uncontrolled by oral corticosteroids AB Science SA (NYSE Euronext -...
Equillium to Host Business Update Call on October 1, 2019
17 sept. 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at H. C. Wainwright 21st Annual Global Investment Conference
27 août 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma
10 juil. 2019 08h07 HE
|
Equillium
LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium to Present at Jefferies 2019 Healthcare Conference
23 mai 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Expands Scientific and Clinical Advisory Team
06 mai 2019 08h30 HE
|
Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...